Pharma: Page 2
-
Amgen to lay off 350 Horizon staffers weeks after closing $28B deal
The latest round of cuts brings the company’s total announced workforce reductions this year to more than 1,000.
By Kristin Jensen • Oct. 25, 2023 -
Novartis delays FDA filing for in-demand radiopharma drug
Mixed survival data from a study of Pluvicto in earlier prostate cancer sparked the slower regulatory timeline.
By Jonathan Gardner • Oct. 24, 2023 -
Explore the Trendline➔
luismmolina via Getty ImagesTrendlineThe expanding world of RNA therapies
Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.
By BioPharma Dive staff -
J&J medtech head Ashley McEvoy to step down
McEvoy is leaving the company after 27 years to pursue other opportunities. Tim Schmid will now lead the MedTech business.
By Elise Reuter • Updated Oct. 24, 2023 -
Sponsored by Target RWE
Leveraging real-world evidence with analytics: 3 essential components to capture a 360-degree view of your patient population
Three essential components to create impactful real-world evidence with a 360-degree patient journey.
By Ewa Kleczyk, PhD, SVP, Commercial Analytics & Data Curation • Oct. 23, 2023 -
Merck allies with Daiichi Sankyo in major bet on antibody cancer drugs
The deal is worth up to $22 billion in total, making it one of the largest pharmaceutical licensing agreements by value.
By Ned Pagliarulo • Oct. 20, 2023 -
J&J again bumps forecasts on strong immune drug sales
Tuesday’s earnings were the first since J&J officially split off its consumer drug business, now the publicly traded company Kenvue.
By Ned Pagliarulo • Oct. 17, 2023 -
The top biopharma conferences in 2024
A few key meetings remain this year, like AHA and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.
By Ned Pagliarulo • Oct. 16, 2023 -
Pfizer to cut costs, lay off staff on waning demand for COVID products
Sales of Pfizer’s pill Paxlovid and shot Comirnaty have been slower than it anticipated, while a shift to the commercial market for the antiviral drug has been delayed. Shares rose Monday on the reset guidance.
By Ned Pagliarulo • Updated Oct. 16, 2023 -
Pfizer wins FDA approval for its $7B colitis drug
Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.
By Jonathan Gardner • Oct. 13, 2023 -
Research group says FDA found no misconduct in Pfizer Lyme vaccine trial it helped run
Earlier this year Pfizer removed thousands of participants from a study of its Lyme disease shot over concerns the group, Care Access, wasn't meeting clinical practice standards.
By Delilah Alvarado • Oct. 12, 2023 -
Bayer opens California plant to make cell therapies
The pharma plans for the new Berkeley facility to produce clinical, and potentially commercial, supplies of a Parkinson’s disease cell therapy being tested by its subsidiary BlueRock.
By Delilah Alvarado • Oct. 10, 2023 -
GSK partners with Chinese pharma to expand Shingrix sales
The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.
By Delilah Alvarado • Oct. 9, 2023 -
Apellis sales numbers show steady demand for new eye drug, despite safety worries
The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.
By Kristin Jensen • Oct. 5, 2023 -
Moderna claims positive results in early study for combo COVID, flu shot
The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.
By Delilah Alvarado • Oct. 4, 2023 -
Lilly names new diabetes and obesity chief as Mounjaro sales take off
Company veteran Mike Mason, who took leadership of the division four years ago, is retiring and will be replaced by immunology head Patrik Jonsson.
By Jonathan Gardner • Oct. 4, 2023 -
Sandoz spins out of Novartis as standalone generic drugmaker
The spinoff, now complete, is a major step in CEO Vas Narasimhan’s plan to refocus Novartis more tightly around novel prescription drugs and new technologies.
By Kristin Jensen • Oct. 4, 2023 -
J&J, retreating from infectious disease, partners with Sanofi on E. coli vaccine
The French vaccine giant will pay J&J $175 million to share rights to the experimental inoculation, which is currently in Phase 3 testing.
By Kristin Jensen • Oct. 3, 2023 -
Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout
Point Biopharma is one of the most advanced in a group of emerging biotechs working on radioligand therapies for cancer.
By Ned Pagliarulo • Oct. 3, 2023 -
Novartis’ closely watched rare disease drug scores in kidney disorder
Called iptacopan, the experimental medicine has now scored positive results in three late-stage clinical trials, the latest in an uncommon kidney disorder known as IgA nephropathy.
By Jacob Bell • Oct. 2, 2023 -
Sponsored by SAS
Ready for open source in life sciences? Your pharma analytics journey might be
It’s time to adopt open-source technology – but not without security, compliance and guardrails.
By Mark Lambrecht, Senior Director, Health and Life Sciences Practice • Oct. 2, 2023 -
Novo Nordisk, Evotec partner in metabolic disease drug discovery pact
Hunting for more metabolic disease drugs, Novo plans to work with Evotec to shape early academic research into new development programs.
By Gwendolyn Wu • Sept. 26, 2023 -
Novartis radiopharmaceutical drug succeeds in first-line gut cancer study
Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.
By Jonathan Gardner • Sept. 25, 2023 -
New Alzheimer's drugs
Eisai’s Alzheimer’s drug Leqembi approved in Japan
Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.
By Ned Pagliarulo • Sept. 25, 2023 -
Sponsored by Viatris
Driving innovation to benefit people living with MS
A holistic approach to R&D is key to support MS patients throughout their treatment journey.
By Pat Vallano, Ph.D., Head of Innovative Programs, R&D, Viatris • Sept. 25, 2023 -
AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors
Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.
By Jonathan Gardner • Sept. 22, 2023